Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Autoimmune Disorders01:29

Autoimmune Disorders

2.0K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
2.0K
T Cell Types and Functions01:24

T Cell Types and Functions

2.9K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.9K
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

656
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
656
What is the Immune System?01:38

What is the Immune System?

138.0K
Overview
138.0K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Post-streptococcal Autoimmunity and Its Relevance to Epstein-Barr virus as the Potential Cause of Multiple Sclerosis.

The Journal of infectious diseases·2026
Same author

Are acute asthma presentations to the emergency department an opportunity for optimising long-term management? A qualitative study on beliefs and behaviours of healthcare professionals.

Emergency medicine journal : EMJ·2025
Same author

Sex and gender reporting in UK emergency medicine trials from 2010 to 2023: a systematic review.

Emergency medicine journal : EMJ·2024
Same author

Immunogenicity of biologics used in the treatment of asthma.

Human antibodies·2024
Same author

Cessation of Smoking Trial in the Emergency Department (COSTED): a multicentre randomised controlled trial.

Emergency medicine journal : EMJ·2024
Same author

Neutropenia following immune-depletion, notably CD20 targeting, therapies in multiple sclerosis.

Multiple sclerosis and related disorders·2024
Same journal

Compartment-specific miRNA-gene expression patterns in relapsing-remitting multiple sclerosis: Clinical blood and cerebrospinal fluid validation.

Multiple sclerosis and related disorders·2026
Same journal

Neuromyelitis optica spectrum disorder: a 5-year experience in a tertiary hospital in Northern Vietnam.

Multiple sclerosis and related disorders·2026
Same journal

Cell-type-specific Mendelian randomization analysis of brain single-nucleus eQTLs and neuromyelitis optica spectrum disorder risk.

Multiple sclerosis and related disorders·2026
Same journal

Detection of Aquaporin-4 antibody in cerebrospinal fluid in neuromyelitis optica spectrum disorder.

Multiple sclerosis and related disorders·2026
Same journal

Adjunctive gypenosides for acute optic neuritis: A prematurely terminated randomized, double-blind, placebo-controlled pilot trial in a cohort with frequent AQP4-IgG positivity.

Multiple sclerosis and related disorders·2026
Same journal

Genetic and molecular architecture of multiple sclerosis in gulf cooperation council populations: A scoping review and regional precision-neurology perspective.

Multiple sclerosis and related disorders·2026
See all related articles

Related Experiment Video

Updated: Mar 3, 2026

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.4K

Multiple sclerosis and autoimmunity: learnings from post-streptococcal autoimmunity.

Benjamin Michael Bloom1, Olivia Payne2, Ester Valero-Hernandez3

  • 1Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK; Emergency Department, Royal London Hospital, Barts Health NHS Trust, London E1 1BB, UK.

Multiple Sclerosis and Related Disorders
|March 1, 2026
PubMed
Summary
This summary is machine-generated.

Treating Epstein-Barr virus (EBV) infections, like infectious mononucleosis (IM), may prevent or reduce multiple sclerosis (MS) risk. Antiviral therapies could also prevent MS relapses and disability.

Keywords:
Epstein-Barr virusMultiple sclerosisPost-streptococcal autoimmunityStreptococcus

More Related Videos

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.7K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.9K

Related Experiment Videos

Last Updated: Mar 3, 2026

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.4K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.7K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.9K

Area of Science:

  • Immunology
  • Neurology
  • Infectious Diseases

Background:

  • Group A Streptococcus (GAS) causes acute rheumatic fever (ARF), preventable with antibiotics.
  • Epstein-Barr virus (EBV) is implicated in multiple sclerosis (MS) development.
  • Infectious mononucleosis (IM), caused by EBV, is a risk factor for MS.

Purpose of the Study:

  • To hypothesize that treating EBV infections could prevent or reduce MS incidence.
  • To explore antiviral therapies for preventing MS relapses and disability.

Main Methods:

  • Analogy drawn from GAS and ARF prevention strategies.
  • Hypothesized role of EBV in MS pathogenesis.
  • Proposed exploration of antiviral treatments for IM and MS.

Main Results:

  • No direct results presented; hypothesis-driven exploration proposed.
  • Potential for antivirals to mitigate MS risk and progression.
  • Need for further research into EBV-targeted MS therapies.

Conclusions:

  • Treating IM with antivirals may prevent MS.
  • Chronic antiviral treatment could prevent MS relapses and disability.
  • Targeting EBV is a potential strategy for MS prevention and treatment.